Usefulness of monitoring sunitinib plasma concentration for the patients with metastatic renal cell carcinoma

Usefulness of monitoring sunitinib plasma concentration for the patients with metastatic renal cell carcinoma - Monitoring for plasma concentration of sunitinib

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043378

Enrollment

Registered

2021-02-19

Start date

2013-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic renal cell carcinoma

Interventions

Periods: to finish of sunitinib treatment Amount: standard Periods: to finish of sunitinib treatment Amount: alternative

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients with metastatic renal cell carcinoma who have measurable regions 2 Patients who are scheduled sunitinib treatment

Exclusion criteria

Exclusion criteria: 1 with liver and/or renal dysfunction (over ULNx2) 2 with severe heart failure

Design outcomes

Primary

Measure	Time frame
sunitinib plasma concentration	—

Secondary

Measure	Time frame
progression free survival periods, rate of adverse events	—

Countries

Japan

Contacts

Public ContactKojiro Ohba

Nagasaki University Hospital Department of Urology and Renal Transplantation

ohba-k@nagasaki-u.ac.jp+81958197340

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026